BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 32616659)

  • 1. BET 2: Hydroxychloroquine in the treatment of COVID-19.
    Howard L; Baombe J; Reynard C
    Emerg Med J; 2020 Jul; 37(7):451-453. PubMed ID: 32616659
    [No Abstract]   [Full Text] [Related]  

  • 2. Novel approach for low-dose pulmonary delivery of hydroxychloroquine in COVID-19.
    Fassihi SC; Nabar NR; Fassihi R
    Br J Pharmacol; 2020 Nov; 177(21):4997-4998. PubMed ID: 32562278
    [No Abstract]   [Full Text] [Related]  

  • 3. Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19).
    Gao J; Hu S
    Biosci Trends; 2020 May; 14(2):156-158. PubMed ID: 32281583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proactive Prophylaxis With Azithromycin and HydroxyChloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID): A structured summary of a study protocol for a randomised controlled trial.
    Sivapalan P; Ulrik CS; Bojesen RD; Lapperre TS; Eklöf JV; Håkansson KEJ; Browatzki A; Tidemansen C; Wilcke JT; Janner J; Gottlieb V; Meteran H; Porsbjerg C; Madsen BL; Moberg M; Pedersen L; Benfield TL; Lundgren JD; Knop FK; Biering-Sørensen T; Ghanizada M; Sonne TP; Bødtger UCS; Jensen SG; Rasmussen DB; Brøndum E; Tupper OD; Sørensen SW; Alstrup G; Laursen CB; Møller UW; Sverrild A; Jensen JS
    Trials; 2020 Jun; 21(1):513. PubMed ID: 32522282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety considerations for chloroquine and hydroxychloroquine in the treatment of COVID-19.
    Gevers S; Kwa MSG; Wijnans E; van Nieuwkoop C
    Clin Microbiol Infect; 2020 Sep; 26(9):1276-1277. PubMed ID: 32422406
    [No Abstract]   [Full Text] [Related]  

  • 6. Test and treat COVID 65 plus - Hydroxychloroquine versus placebo in early ambulatory diagnosis and treatment of older patients with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Göpel S; Bethge W; Martus P; Kreth F; Iftner T; Joos S; Döbele S; Mordmüller B; Kremsner P; Ettrich T; Seufferlein T; Bitzer M; Malek N
    Trials; 2020 Jul; 21(1):635. PubMed ID: 32650818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial.
    González R; García-Otero L; Pons-Duran C; Marbán-Castro E; Goncé A; Llurba E; Gil MDM; Rodríguez-Zambrano MÁ; Chen H; Ramírez M; Bardají A; Menendez C
    Trials; 2020 Jul; 21(1):607. PubMed ID: 32616063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychiatric implications of the use of hydroxychloroquine in COVID-19 patients.
    Rani S; Grover S; Mehra A; Sahoo S
    Indian J Pharmacol; 2020; 52(3):229-231. PubMed ID: 32874009
    [No Abstract]   [Full Text] [Related]  

  • 9. Does hydroxychloroquine combat COVID-19? A timeline of evidence.
    Alia E; Grant-Kels JM
    J Am Acad Dermatol; 2020 Jul; 83(1):e33-e34. PubMed ID: 32283236
    [No Abstract]   [Full Text] [Related]  

  • 10. Covid-19 treatment update: follow the scientific evidence.
    Becker RC
    J Thromb Thrombolysis; 2020 Jul; 50(1):43-53. PubMed ID: 32338320
    [No Abstract]   [Full Text] [Related]  

  • 11. COVID-19 and hydroxychloroquine: Is the wonder drug failing?
    Paliani U; Cardona A
    Eur J Intern Med; 2020 Aug; 78():1-3. PubMed ID: 32553587
    [No Abstract]   [Full Text] [Related]  

  • 12. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
    Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
    Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.
    Bosaeed M; Mahmoud E; Hussein M; Alharbi A; Alsaedy A; Alothman A; Aljeraisy M; Alqahtani H; Nashabat M; Almutairi B; Almaghaslah M; Aldibasi O; AlJohani S; Bouchama A; Arabi Y; Alaskar A
    Trials; 2020 Oct; 21(1):904. PubMed ID: 33129363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BET 1: Lopinavir-ritonavir and COVID-19.
    Dolan D; Ingham J; Baombe J
    Emerg Med J; 2020 Jul; 37(7):450-451. PubMed ID: 32616658
    [No Abstract]   [Full Text] [Related]  

  • 15. Hydroxychloroquine and azithromycin as potential treatments for COVID-19; clinical status impacts the outcome.
    Okour M; Al-Kofahi M; Austin D
    J Pharmacokinet Pharmacodyn; 2020 Jun; 47(3):187-188. PubMed ID: 32405664
    [No Abstract]   [Full Text] [Related]  

  • 16. ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured summary of a study protocol for a randomised controlled trial.
    McEniery CM; Fisk M; Miles K; Kaloyirou F; Hubsch A; Smith J; Wilkinson IB; Cheriyan J
    Trials; 2020 Jul; 21(1):604. PubMed ID: 32616067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The COVIRL-001 Trial: A multicentre, prospective, randomised trial comparing standard of care (SOC) alone, SOC plus hydroxychloroquine monotherapy or SOC plus a combination of hydroxychloroquine and azithromycin in the treatment of non- critical, SARS-CoV-2 PCR-positive population not requiring immediate resuscitation or ventilation but who have evidence of clinical decline: A structured summary of a study protocol for a randomised controlled trial.
    Feeney E; Wallace D; Cotter A; Tinago W; McCarthy C; Keane D; Hussain R; Alvarez Barco E; Doran P; Mallon P
    Trials; 2020 May; 21(1):430. PubMed ID: 32450915
    [No Abstract]   [Full Text] [Related]  

  • 18. Do we have enough evidence to use chloroquine/hydroxychloroquine as a public health panacea for COVID-19?
    Palmeira VA; Costa LB; Perez LG; Ribeiro VT; Lanza K; Silva ACSE
    Clinics (Sao Paulo); 2020; 75():e1928. PubMed ID: 32401962
    [No Abstract]   [Full Text] [Related]  

  • 19. A Call for Randomized Controlled Trials to Test the Efficacy of Chloroquine and Hydroxychloroquine as Therapeutics against Novel Coronavirus Disease (COVID-19).
    Keshtkar-Jahromi M; Bavari S
    Am J Trop Med Hyg; 2020 May; 102(5):932-933. PubMed ID: 32247318
    [No Abstract]   [Full Text] [Related]  

  • 20. Chloroquine and Hydroxychloroquine in COVID-19: Challenges and the Need for Caution in Low-Resource Settings.
    Islam M
    J Coll Physicians Surg Pak; 2020 Jun; 30(6):78. PubMed ID: 32723461
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.